MCID: THY028
MIFTS: 68

Thyroid Cancer

Categories: Cancer diseases, Genetic diseases, Endocrine diseases

Aliases & Classifications for Thyroid Cancer

MalaCards integrated aliases for Thyroid Cancer:

Name: Thyroid Cancer 12 29 29 52 41 14
Thyroid Carcinoma 12 24 29 52 14 69
Thyroid Neoplasm 12 69
Malignant Neoplasm of Thyroid Gland 12
Malignant Tumour of Thyroid Gland 12
Head and Neck Cancer, Thyroid 12
Neoplasm of the Thyroid Gland 29
Malignant Neoplasm of Thyroid 69
Neoplasm of Thyroid Gland 12
Thyroid Gland Neoplasm 12
Thyroid Neoplasms 42

Classifications:



External Ids:

Disease Ontology 12 DOID:1781 DOID:3963
ICD10 33 C73
ICD9CM 35 193
MeSH 42 D013964

Summaries for Thyroid Cancer

MedlinePlus : 41 your thyroid is a butterfly-shaped gland in your neck, just above your collarbone. it makes hormones that help the body work normally. there are several types of cancer of the thyroid gland. you are at greater risk if you are between ages 25 and 65 are a woman are asian have a family member who has had thyroid disease have had radiation treatments to your head or neck you should see a doctor if you have a lump or swelling in your neck. doctors use a physical exam, thyroid tests, other blood and imaging tests, and a biopsy to diagnose thyroid cancer. treatment depends on the type of cancer you have and how far the cancer has spread. many patients receive a combination of treatments. they may include surgery, radioactive iodine, hormone treatment, radiation therapy, chemotherapy, or targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards based summary : Thyroid Cancer, also known as thyroid carcinoma, is related to medullary thyroid carcinoma, familial and lymphoma, and has symptoms including coughing, snoring and sore throat. An important gene associated with Thyroid Cancer is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Thyroid cancer and MAPK-Erk Pathway. The drugs Cometriq and Lenvima have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and endothelial, and related phenotypes are Decreased viability and homeostasis/metabolism

Disease Ontology : 12 A thyroid cancer that has material basis in epithelial cells.

Wikipedia : 72 Thyroid cancer is cancer that develops from the tissues of the thyroid gland. It is a disease in which... more...

Related Diseases for Thyroid Cancer

Diseases related to Thyroid Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 240)
id Related Disease Score Top Affiliating Genes
1 medullary thyroid carcinoma, familial 33.3 CALCA NKX2-1 NTRK1 RET TG
2 lymphoma 30.7 TG TPO TSHR
3 endemic goiter 30.5 CALCA TG TPO TSHR
4 thyroid cancer, nonmedullary, 1 12.2
5 thyroid cancer, nonmedullary, 2 12.2
6 thyroid cancer, nonmedullary, 5 12.2
7 thyroid cancer, anaplastic 12.1
8 thyroid cancer, nonmedullary, 4 12.1
9 thyroid cancer, childhood 11.9
10 thyroid carcinoma, hurthle cell 11.6
11 thyroiditis 11.1
12 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form 11.0 FOXE1 HABP2
13 hypothyroidism 11.0
14 raf1-related noonan syndrome 11.0 BRAF NRAS
15 tmem38b-related osteogenesis imperfecta 11.0 BRAF RET
16 epidermal nevus, somatic 11.0 HRAS NRAS
17 retinitis pigmentosa 27 11.0 HRAS NKX2-1
18 malignant skin fibrous histiocytoma 11.0 HRAS KRAS
19 bladder tuberculosis 10.9 CDH1 TG
20 familial papillary thyroid carcinoma 10.9
21 childhood mediastinal neurogenic tumor 10.9 CALCA TG
22 familial schizencephaly, shh-related 10.9 HABP2 NTRK1 RET
23 schimmelpenning-feuerstein-mims syndrome, somatic mosaic 10.9 HRAS KRAS NRAS
24 split hand split foot nystagmus 10.9 BRAF HRAS
25 breast adenoid cystic carcinoma 10.9 HRAS KRAS NKX2-1
26 gorham's disease 10.9 HRAS KRAS RET
27 limb ischemia 10.9 HRAS KRAS
28 occupational dermatitis 10.9 HRAS KRAS NRAS
29 dubin-johnson syndrome 10.9 BRAF HRAS NRAS
30 dyserythropoietic anemia and thrombocytopenia 10.9 HRAS KRAS NRAS
31 ossifying fibromyxoid tumor 10.9 HRAS KRAS NRAS
32 radioulnar synostosis 10.9 BRAF HRAS KRAS
33 maxillary sinus adenoid cystic carcinoma 10.9 TG TPO
34 parietal lobe neoplasm 10.8 CALCA FOXE1 TG
35 olfactory neuroblastoma 10.8 HRAS KRAS NKX2-1
36 corneal ectasia 10.8 CALCA TG
37 male reproductive organ benign neoplasm 10.8 HRAS KRAS RET
38 peritoneal serous adenocarcinoma 10.8 CDH1 HRAS KRAS
39 gastrointestinal neuroendocrine tumor 10.8 CDH1 HRAS KRAS
40 fallopian tube leiomyoma 10.8 CALCA NKX2-1 TG
41 maxillary neoplasm 10.8 CDH1 HRAS KRAS
42 noonan syndrome 7 10.8 BRAF HRAS KRAS
43 gastric cancer risk after h. pylori infection 10.8 CDH1 KRAS
44 pancreatic somatostatinoma 10.8 CDH1 HRAS KRAS
45 seminal vesicle chronic gonorrhea 10.8 CALCA HRAS KRAS
46 c5 deficiency 10.8 FOXE1 TG TPO
47 kidney disease 10.8 NKX2-1 RET TG TSHR
48 cervical endometrial stromal sarcoma 10.8 CALCA TG
49 ntrk1-related familial medullary thyroid carcinoma 10.8
50 trachea squamous cell carcinoma 10.8 CDH1 HRAS KRAS

Comorbidity relations with Thyroid Cancer via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism
Lymphomatous Thyroiditis Postsurgical Hypothyroidism

Graphical network of the top 20 diseases related to Thyroid Cancer:



Diseases related to Thyroid Cancer

Symptoms & Phenotypes for Thyroid Cancer

UMLS symptoms related to Thyroid Cancer:


coughing, snoring, sore throat, vertigo/dizziness, equilibration disorder

GenomeRNAi Phenotypes related to Thyroid Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.95 KRAS HRAS BRAF
2 Decreased viability GR00106-A-0 9.95 KRAS
3 Decreased viability GR00221-A-1 9.95 KRAS RET CDH1 HRAS NRAS PPARG
4 Decreased viability GR00221-A-2 9.95 PPARG KRAS RET HRAS
5 Decreased viability GR00221-A-3 9.95 PPARG NTRK1 HRAS NRAS
6 Decreased viability GR00221-A-4 9.95 RET BRAF PPARG
7 Decreased viability GR00231-A 9.95 RET
8 Decreased viability GR00301-A 9.95 KRAS RET NTRK1 CDH1 BRAF
9 Decreased viability GR00381-A-1 9.95 KRAS BRAF

MGI Mouse Phenotypes related to Thyroid Cancer:

44 (show all 20)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 RET TG TPO TSHR BRAF CDH1
2 growth/size/body region MP:0005378 10.39 BRAF CDH1 FOXE1 HRAS KRAS NKX2-1
3 endocrine/exocrine gland MP:0005379 10.37 NRAS PAX8 PPARG RET TG TPO
4 behavior/neurological MP:0005386 10.33 PPARG RET TSHR BRAF HRAS KRAS
5 mortality/aging MP:0010768 10.33 BRAF CDH1 FOXE1 HABP2 HRAS KRAS
6 cardiovascular system MP:0005385 10.28 BRAF CDH1 HRAS KRAS LGALS3 NKX2-1
7 immune system MP:0005387 10.25 BRAF CDH1 HABP2 KRAS LGALS3 NRAS
8 digestive/alimentary MP:0005381 10.17 NKX2-1 NRAS RET BRAF CDH1 FOXE1
9 integument MP:0010771 10.15 BRAF CDH1 FOXE1 HRAS KRAS LGALS3
10 nervous system MP:0003631 10.14 BRAF HRAS KRAS LGALS3 NKX2-1 NTRK1
11 neoplasm MP:0002006 10.13 BRAF CDH1 HRAS KRAS LGALS3 NKX2-1
12 hearing/vestibular/ear MP:0005377 10.08 BRAF KRAS NTRK1 PAX8 PPARG TPO
13 craniofacial MP:0005382 10.05 BRAF FOXE1 HRAS KRAS NRAS PAX8
14 limbs/digits/tail MP:0005371 10.02 KRAS NRAS NTRK1 PAX8 RET TPO
15 no phenotypic analysis MP:0003012 10.02 CDH1 HRAS KRAS NKX2-1 NRAS NTRK1
16 normal MP:0002873 10.02 HRAS KRAS NKX2-1 NRAS NTRK1 PAX8
17 reproductive system MP:0005389 9.81 RET TSHR NKX2-1 PAX8 PPARG BRAF
18 renal/urinary system MP:0005367 9.8 BRAF HRAS KRAS LGALS3 PAX8 PPARG
19 skeleton MP:0005390 9.61 BRAF HRAS KRAS LGALS3 NKX2-1 PAX8
20 vision/eye MP:0005391 9.23 KRAS NRAS NTRK1 PAX8 PPARG TPO

Drugs & Therapeutics for Thyroid Cancer

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Cometriq 17 46 CABOZANTINIB S-MALATE Exelixis November 2012
2
Lenvima 17 46 LENVATINIB MESYLATE Eisai February 2015
3
Nexavar 17 46 SORAFENIB TOSYLATE Bayer/Onyx December 2005
4
Vandetanib 17 46 vandetanib AstraZeneca April 2011

Drugs for Thyroid Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 394)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diazepam Approved, Illicit, Vet_approved Phase 4,Phase 1 439-14-5 3016
2
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
5
Iodine Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 7553-56-2 807
6 cadexomer iodine Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
7 glucocorticoids Phase 4,Phase 2,Phase 1
8 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
9 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
10 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
11 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
12 Hormones Phase 4,Phase 3,Phase 1,Phase 2
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
15 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
16 Anti-Infective Agents, Local Phase 4,Phase 2,Phase 3,Phase 1
17 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1
18 Analgesics Phase 4,Phase 2
19 Respiratory System Agents Phase 4,Phase 3
20 Adjuvants, Anesthesia Phase 4,Phase 1
21 Narcotics Phase 4
22 Analgesics, Opioid Phase 4
23 Anesthetics Phase 4,Phase 3,Phase 1
24 Anesthetics, General Phase 4,Phase 1
25 Anesthetics, Intravenous Phase 4,Phase 1
26 Anti-Asthmatic Agents Phase 4,Phase 3
27 Betamethasone Valerate Phase 4 2152-44-5
28 Betamethasone acetate Phase 4
29 Betamethasone benzoate Phase 4
30 Betamethasone sodium phosphate Phase 4
31 Betamethasone-17,21-dipropionate Phase 4
32 tyrosine Nutraceutical Phase 4,Phase 2,Phase 1
33 Citrate Nutraceutical Phase 4,Phase 2,Phase 1
34
Citric Acid Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 77-92-9 311
35
Paclitaxel Approved, Vet_approved Phase 2, Phase 3, Phase 1, Early Phase 1 33069-62-4 36314
36
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
37
Salmon Calcitonin Approved, Investigational Phase 3,Phase 2,Phase 1 47931-85-1 16129616
38
Lenvatinib Approved Phase 3,Phase 2,Phase 1 417716-92-8
39
Zinc Approved Phase 3 7440-66-6 32051 23994
40
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 498142 38904
41
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
42
Metformin Approved Phase 3,Phase 2 657-24-9 14219 4091
43
Octreotide Approved, Investigational Phase 3,Phase 1 83150-76-9 383414 6400441
44
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
45
Insulin Glargine Approved Phase 3 160337-95-1
46 Dulaglutide Approved Phase 3 923950-08-7
47 Racepinephrine Approved Phase 3,Phase 2
48
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
49
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 1406-16-2
50
Ergocalciferol Approved, Nutraceutical Phase 3,Phase 2 50-14-6 5280793

Interventional clinical trials:

(show top 50) (show all 590)

id Name Status NCT ID Phase Drugs
1 rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4 rAd-p53 gene;p53 gene therapy
2 Total Thyroidectomy With Harmonic Scalpel® Unknown status NCT00385983 Phase 4
3 Dental Safety Profile of High-Dose Radioiodine Therapy Completed NCT00439478 Phase 4 Radioiodine
4 Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer Completed NCT00604318 Phase 4 rhTSH
5 A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours Completed NCT01736163 Phase 4 Thyrogen;131I
6 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4 Thyrogen
7 Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia Completed NCT01308320 Phase 4 fentanyl citrate;saline
8 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
9 Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results Completed NCT00858104 Phase 4
10 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
11 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
12 Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy Recruiting NCT02946918 Phase 4 Levothyroxine
13 Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Recruiting NCT02652884 Phase 4 phosphate and betamethasone acetate, 2 mL.;saline 0.9% NaCl
14 To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
15 Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer Unknown status NCT00704730 Phase 3 XL184;Placebo
16 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
17 Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy Unknown status NCT01551914 Phase 3
18 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
19 Laser Therapy of Benign Thyroid Nodules Unknown status NCT00150150 Phase 3
20 Improved Preoperative Selection of Cold Thyroid Nodules Unknown status NCT00297297 Phase 3
21 Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer Completed NCT01083550 Phase 2, Phase 3
22 Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Completed NCT01876784 Phase 3 Vandetanib (SAR390530);Placebo
23 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
24 The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer Completed NCT00794053 Phase 3
25 rhTSH-Thyroid Ablation With 1850 MBq of 131I Completed NCT00454077 Phase 3
26 Multicenter Study Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
27 Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC Completed NCT01137097 Phase 2, Phase 3
28 Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients Completed NCT01616316 Phase 2, Phase 3
29 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Completed NCT00795782 Phase 3
30 Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration Completed NCT00196729 Phase 3 Thyrogen + Radioiodine (131I)
31 Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy Completed NCT02112370 Phase 3 Ropivacaine with epinephrine injection
32 Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain Completed NCT01126060 Phase 3 Usage of Fibrin sealant
33 Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer Completed NCT00123760 Phase 2, Phase 3
34 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
35 A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes Completed NCT02152371 Phase 3 Dulaglutide;Placebo;Insulin Glargine;Metformin
36 Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules Completed NCT01649206 Phase 3
37 Elastography Interest in the Management of Thyroid Nodules Completed NCT01335828 Phase 2, Phase 3
38 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
39 Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer Recruiting NCT03048877 Phase 3 Apatinib Oral Tablet;Placebo Oral Tablet
40 A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China Recruiting NCT02966093 Phase 3 Lenvatinib;Placebo
41 Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) Recruiting NCT02586337 Phase 2, Phase 3 Anlotinib;Placebo
42 Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? Recruiting NCT01837745 Phase 3 rhTSH stimulation;I131
43 Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) Recruiting NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
44 Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Recruiting NCT01149161 Phase 2, Phase 3
45 A Study to Compare the Safety and Imaging Pattern of Cyclotron-produced Technetium (CTC) vs. Generator-produced Technetium (G-PERT) in People With Thyroid Disorders Who Need Surgery Recruiting NCT02980679 Phase 3 CTC;G-PERT
46 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
47 Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer Active, not recruiting NCT01843062 Phase 3 Selumetinib;Placebo;Radioactive Iodine Therapy
48 An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
49 Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer Active, not recruiting NCT02418247 Phase 2, Phase 3 I131;I123
50 Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid Cancer Active, not recruiting NCT01074684 Phase 3

Search NIH Clinical Center for Thyroid Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: thyroid neoplasms

Genetic Tests for Thyroid Cancer

Genetic tests related to Thyroid Cancer:

id Genetic test Affiliating Genes
1 Thyroid Carcinoma 29 24
2 Neoplasm of the Thyroid Gland 29
3 Thyroid Cancer 29

Anatomical Context for Thyroid Cancer

MalaCards organs/tissues related to Thyroid Cancer:

39
Thyroid, Lymph Node, Endothelial, Testes, Lung, Bone, Prostate

Publications for Thyroid Cancer

Articles related to Thyroid Cancer:

(show top 50) (show all 2110)
id Title Authors Year
1
Genetics of medullary thyroid cancer: An overview. ( 28506408 )
2017
2
"Pseudo-progression" in advanced thyroid cancer in response to kinase inhibitor therapy. ( 28509079 )
2017
3
REFERRAL OF OLDER THYROID CANCER PATIENTS TO A HIGH-VOLUME SURGEON: RESULTS OF A MULTIDISCIPLINARY PHYSICIAN SURVEY. ( 28534681 )
2017
4
ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer. ( 27935748 )
2017
5
Effect of Slug-Mediated Down-Regulation of E-Cadherin on Invasiveness and Metastasis of Anaplastic Thyroid Cancer Cells. ( 28070118 )
2017
6
Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer. ( 27849428 )
2017
7
Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer. ( 28953211 )
2017
8
Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. ( 28911730 )
2017
9
Comprehensive gene and microRNA expression profiling reveals a role for miRNAs in the oncogenic roles of SphK1 in papillary thyroid cancer. ( 27942860 )
2017
10
MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer. ( 28061868 )
2017
11
Effects of long non-coding RNA H19 and microRNA let7a expression on thyroid cancer prognosis. ( 28655518 )
2017
12
EphB3 Stimulates Cell Migration and Metastasis in a Kinase-dependent Manner through Vav2-Rho GTPase Axis in Papillary Thyroid Cancer. ( 27986811 )
2017
13
The central compartment - Center of controversy, confusion, and concern in management of differentiated thyroid cancer. ( 28916416 )
2017
14
Follow-up of patients with thyroglobulin-antibodies: Rising Tg-Ab trend is a risk factor for recurrence of differentiated thyroid cancer. ( 28509618 )
2017
15
Notch3 expression correlates with thyroid cancer differentiation, induces apoptosis, and predicts disease prognosis. ( 27861750 )
2017
16
De novo thyroid cancer following solid organ transplantation-A 25-year experience at a high-volume institution with a review of the literature. ( 28054345 )
2017
17
Immune response in the thyroid cancer microenvironment: making immunotherapy a possible mission. ( 28912377 )
2017
18
Deregulated expression of VHL mRNA variants in papillary thyroid cancer. ( 28089820 )
2017
19
Changes in thyroid cancer incidence, post-2009 American Thyroid Association guidelines. ( 28092116 )
2017
20
Intravoxel incoherent motion magnetic resonance imaging of the normal-appearing parotid glands in patients with differentiated thyroid cancer after radioiodine therapy. ( 28530137 )
2017
21
Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer. ( 28516448 )
2017
22
HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E. ( 28423638 )
2017
23
Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer. ( 28926589 )
2017
24
Association of PDCD1 gene markers with susceptibility to thyroid cancer. ( 27943063 )
2017
25
Knockdown of lncRNA-PANDAR suppresses the proliferation, cell cycle and promotes apoptosis in thyroid cancer cells. ( 28507479 )
2017
26
Current Management of Low Risk Differentiated Thyroid Cancer and Papillary Microcarcinoma. ( 28087101 )
2017
27
Differential regulation of monocarboxylate transporter 8 expression in thyroid cancer and hyperthyroidism. ( 28576880 )
2017
28
HABP2 G534E variation in familial non-medullary thyroid cancer: an Italian series. ( 27873212 )
2017
29
Effects of prolonged exposure to low dose metformin in thyroid cancer cell lines. ( 28529619 )
2017
30
The Association of Thyrotropin and Autoimmune Thyroid Disease in Developing Papillary Thyroid Cancer. ( 28951739 )
2017
31
Role of KrA1ppel-like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer. ( 28920531 )
2017
32
Thyroid cancer 1 (C8orf4) shows high expression, no mutation and reduced methylation level in lung cancers, and its expression correlates with I^-catenin and DNMT1 expression and poor prognosis. ( 28430656 )
2017
33
Benign breast disease and risk of thyroid cancer. ( 28681104 )
2017
34
Pictorial Review of False-Positive Results on Radioiodine Scintigrams of Patients with Differentiated Thyroid Cancer. ( 28076008 )
2017
35
Contribution of industrial density and socioeconomic status to the spatial distribution of thyroid cancer risk in Hangzhou, China. ( 28938210 )
2017
36
Thyroid function after TSH suppression for thyroid cancer: When is optimal time to check? ( 28504824 )
2017
37
Impact of Radioguided Occult Lesion Localization (ROLL) in the management of cervical recurrences from differentiated thyroid cancer. ( 28933526 )
2017
38
Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer. ( 28255192 )
2017
39
LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer. ( 28260052 )
2017
40
Anti-thyroglobulin antibodies do not significantly increase the risk of finding iodine avid metastases on post-radioactive iodine ablation scan in low-risk thyroid cancer patients. ( 28510122 )
2017
41
Morbidity of central compartment clearance: Comparison of lesser versus complete clearance in patients with thyroid cancer. ( 28508841 )
2017
42
Deltopectoral flap revisited for reconstruction surgery in patients with advanced thyroid cancer: a case report. ( 28915833 )
2017
43
Endocrine disruptors: Flame retardants and increased risk of thyroid cancer. ( 28937689 )
2017
44
Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer. ( 27919446 )
2017
45
Inverse expression of caveolin-1 and EGFR in thyroid cancer patients. ( 27818286 )
2017
46
SIRT6 is upregulated and associated with cancer aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcla891 pathway. ( 28393212 )
2017
47
MYH9 binds to lncRNA gene PTCSC2 and regulates FOXE1 in the 9q22 thyroid cancer risk locus. ( 28049826 )
2017
48
Cell division cycle 45 promotes papillary thyroid cancer progression via regulating cell cycle. ( 28474999 )
2017
49
Knockdown of SOX9 Inhibits the Proliferation, Invasion, and EMT in Thyroid Cancer Cells. ( 28277188 )
2017
50
MREG suppresses thyroid cancer cell invasion and proliferation by inhibiting Akt-mTOR signaling. ( 28698135 )
2017

Variations for Thyroid Cancer

ClinVar genetic disease variations for Thyroid Cancer:

6 (show all 32)
id Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
2 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
3 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
4 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
5 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
6 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
7 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh37 Chromosome 12, 25398282: 25398282
8 HRAS NM_005343.3(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
9 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
10 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
11 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
12 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
13 RET NM_020630.4(RET): c.1902C> G (p.Cys634Trp) single nucleotide variant Pathogenic/Likely pathogenic rs77709286 GRCh37 Chromosome 10, 43609950: 43609950
14 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic/Likely pathogenic rs74799832 GRCh37 Chromosome 10, 43617416: 43617416
15 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
16 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
17 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
18 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh37 Chromosome 7, 140453133: 140453133
19 KRAS NM_033360.3(KRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs121913240 GRCh37 Chromosome 12, 25380276: 25380276
20 KRAS NM_033360.3(KRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913240 GRCh37 Chromosome 12, 25380276: 25380276
21 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275
22 KRAS NM_033360.3(KRAS): c.38G> T (p.Gly13Val) single nucleotide variant drug response rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
23 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
24 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh37 Chromosome 3, 178952074: 178952074
25 KRAS NM_004985.4(KRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic rs121913238 GRCh37 Chromosome 12, 25380277: 25380277
26 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
27 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh38 Chromosome 1, 114713907: 114713907
28 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
29 HRAS; LRRC56 NM_005343.3(HRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
30 KRAS NM_004985.4(KRAS): c.437C> T (p.Ala146Val) single nucleotide variant Pathogenic rs1057519725 GRCh37 Chromosome 12, 25378561: 25378561
31 KRAS NM_004985.4(KRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913240 GRCh37 Chromosome 12, 25380276: 25380276
32 KRAS NM_033360.3(KRAS): c.37G> A (p.Gly13Ser) single nucleotide variant Pathogenic rs121913535 GRCh37 Chromosome 12, 25398282: 25398282

Copy number variations for Thyroid Cancer from CNVD:

7 (show all 22)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 48476 11 1 43400000 Gain Thyroid cancer
2 75266 13 18400000 72100000 Loss Thyroid cancer
3 80538 13 93800000 114142980 Loss Thyroid cancer
4 85051 14 37800000 43500000 Copy number FOXA1 Thyroid cancer
5 96631 15 90931472 91045475 Amplificationlicatio n IQGAP1 Thyroid cancer
6 111285 17 35400000 68400000 Gain Thyroid cancer
7 120295 18 23300000 71300000 Loss Thyroid cancer
8 150420 20 1 27100000 Amplification Thyroid cancer
9 151957 20 27100000 62435964 Amplification Thyroid cancer
10 153452 20 37100000 62435964 Gain Thyroid cancer
11 171643 3 170900000 182700000 Gain PIK3CA Thyroid cancer
12 171644 3 170900000 182700000 Gain PIK3CA Thyroid cancer
13 191662 5 1 45800000 Amplification Thyroid cancer
14 191664 5 1 45800000 Gain Thyroid cancer
15 200481 5 55800000 180857866 Gain Thyroid cancer
16 201091 5 65300000 159900000 Amplification Thyroid cancer
17 217036 7 1 158821424 Amplification Thyroid cancer
18 230743 8 1 19100000 Loss Thyroid cancer
19 236403 8 16100000 117700000 Amplification Thyroid cancer
20 236404 8 16100000 146274826 Gain Thyroid cancer
21 261707 X 24900000 59500000 Loss Thyroid cancer
22 303365 21 26028751 26066642 Deletion NRF2 Thyroid cancer

Expression for Thyroid Cancer

Search GEO for disease gene expression data for Thyroid Cancer.

Pathways for Thyroid Cancer

Pathways related to Thyroid Cancer according to KEGG:

37
id Name Kegg Source Accession
1 Thyroid cancer hsa05216

Pathways related to Thyroid Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 BRAF HRAS KRAS NRAS PPARG
2
Show member pathways
12.81 BRAF CDH1 HRAS KRAS NRAS NTRK1
3
Show member pathways
12.73 BRAF CDH1 HRAS KRAS NRAS
4 12.71 BRAF HRAS KRAS NRAS NTRK1
5
Show member pathways
12.49 BRAF CDH1 HRAS KRAS NRAS
6
Show member pathways
12.43 HRAS KRAS NRAS NTRK1
7
Show member pathways
12.4 BRAF HRAS KRAS NRAS
8
Show member pathways
12.39 PAX8 SLC5A5 TG TPO TSHR
9
Show member pathways
12.38 BRAF HRAS KRAS NRAS
10
Show member pathways
12.34 BRAF HRAS KRAS NRAS
11
Show member pathways
12.31 BRAF HRAS KRAS NRAS
12 12.3 BRAF HRAS KRAS NRAS
13
Show member pathways
12.3 BRAF HRAS KRAS NRAS
14
Show member pathways
12.27 BRAF HRAS KRAS NRAS
15
Show member pathways
12.26 BRAF HRAS KRAS NRAS NTRK1
16
Show member pathways
12.25 BRAF CCDC6 CDH1 HRAS KRAS NCOA4
17
Show member pathways
12.2 HRAS KRAS NRAS RET
18
Show member pathways
12.2 BRAF HRAS KRAS NRAS
19
Show member pathways
12.15 HRAS KRAS NRAS PPARG
20
Show member pathways
12.13 BRAF HRAS KRAS NRAS PPARG
21
Show member pathways
12.11 BRAF HRAS KRAS NRAS PPARG
22
Show member pathways
12.1 BRAF HRAS KRAS NRAS
23 12.1 CDH1 HRAS KRAS NRAS
24
Show member pathways
12.09 BRAF HRAS KRAS NRAS
25 12.07 BRAF HRAS KRAS NRAS
26
Show member pathways
12.06 BRAF HRAS KRAS NRAS NTRK1
27 12.03 CDH1 HRAS KRAS NRAS
28 11.99 BRAF HRAS KRAS NRAS
29 11.96 BRAF HRAS KRAS NRAS
30 11.96 BRAF CCDC6 CDH1 HRAS KRAS NCOA4
31 11.94 BRAF HRAS KRAS NRAS
32 11.89 BRAF KRAS PPARG
33
Show member pathways
11.84 HRAS KRAS NRAS
34 11.75 BRAF HRAS KRAS NRAS NTRK1
35
Show member pathways
11.69 BRAF HRAS KRAS NRAS RET
36 11.68 BRAF HRAS PAX8 TSHR
37 11.67 HRAS KRAS NRAS
38
Show member pathways
11.65 BRAF HRAS KRAS NRAS
39 11.6 HRAS KRAS NRAS
40 11.59 BRAF HRAS KRAS NRAS
41 11.58 BRAF CDH1 HRAS KRAS NRAS
42 11.47 HRAS KRAS NRAS NTRK1 RET
43 11.42 HRAS KRAS NRAS RET
44 11.28 HRAS KRAS NRAS
45 11.28 HRAS KRAS NRAS
46
Show member pathways
11.25 HRAS KRAS NRAS
47 11.24 BRAF HRAS KRAS NRAS
48
Show member pathways
11.17 HRAS KRAS NRAS
49 11.11 HRAS KRAS NRAS
50 11.09 HRAS KRAS NRAS

GO Terms for Thyroid Cancer

Biological processes related to Thyroid Cancer according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.89 BRAF HRAS KRAS NKX2-1 RET
2 positive regulation of transcription, DNA-templated GO:0045893 9.8 CDH1 FOXE1 NCOA4 NKX2-1 PAX8 PPARG
3 MAPK cascade GO:0000165 9.77 BRAF HRAS KRAS NRAS RET
4 negative regulation of neuron apoptotic process GO:0043524 9.76 BRAF HRAS KRAS NTRK1
5 Ras protein signal transduction GO:0007265 9.72 HRAS KRAS NRAS
6 epidermal growth factor receptor signaling pathway GO:0007173 9.69 HRAS KRAS NRAS
7 ERBB2 signaling pathway GO:0038128 9.61 HRAS KRAS NRAS
8 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.58 CALCA NTRK1
9 cellular response to nerve growth factor stimulus GO:1990090 9.58 BRAF CALCA NTRK1
10 hormone biosynthetic process GO:0042446 9.57 TG TPO
11 positive regulation of adenylate cyclase activity GO:0045762 9.56 CALCA TSHR
12 response to isolation stress GO:0035900 9.54 HRAS KRAS
13 cellular response to gonadotropin stimulus GO:0071371 9.52 PAX8 SLC5A5
14 iodide transport GO:0015705 9.48 SLC5A5 TG
15 axon guidance GO:0007411 9.43 HRAS KRAS NKX2-1 NRAS NTRK1 RET
16 thyroid hormone generation GO:0006590 9.33 FOXE1 SLC5A5 TPO
17 thyroid-stimulating hormone signaling pathway GO:0038194 9.32 PAX8 TSHR
18 thyroid gland development GO:0030878 9.02 BRAF FOXE1 NKX2-1 PAX8 TG

Molecular functions related to Thyroid Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex binding GO:0032403 9.46 CALCA KRAS NRAS TSHR
2 nucleotide binding GO:0000166 9.35 BRAF HRAS KRAS NRAS RET
3 thyroid-stimulating hormone receptor activity GO:0004996 8.62 PAX8 TSHR

Sources for Thyroid Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....